We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current NRIX market cap is 1.33B. The company's latest EPS is USD -2.5508 and P/E is -6.89.
| Quarter End | Nov 2023 | Feb 2024 | May 2024 | Aug 2024 | Nov 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 15.16M | 16.59M | 12.09M | 12.59M | 13.28M |
| Operating Income | -45.33M | -45.22M | -48.54M | -54.61M | -64.66M |
| Net Income | -41.96M | -41.52M | -44.55M | -48.96M | -58.55M |
| Year End 30 November 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 17.82M | 29.75M | 38.63M | 76.99M | 54.55M |
| Operating Income | -64.98M | -117.89M | -183.87M | -155.06M | -213.03M |
| Net Income | -43.24M | -117.19M | -180.36M | -143.95M | -193.57M |
| Quarter End | Nov 2023 | Feb 2024 | May 2024 | Aug 2024 | Nov 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 355.6M | 312.67M | 511.03M | 513.6M | 669.34M |
| Total Liabilities | 155.11M | 143.93M | 140.34M | 136.74M | 142.35M |
| Total Equity | 200.49M | 168.75M | 370.69M | 376.86M | 526.99M |
| Year End 30 November 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 396.34M | 476.77M | 416.76M | 355.6M | 669.34M |
| Total Liabilities | 106.07M | 134.47M | 113.06M | 155.11M | 142.35M |
| Total Equity | 290.27M | 342.3M | 303.7M | 200.49M | 526.99M |
| Quarter End | Nov 2023 | Feb 2024 | May 2024 | Aug 2024 | Nov 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -81.37M | -41.95M | -81.66M | -123.83M | -172.58M |
| Investing | 68.3M | 35.51M | -95.56M | -116.9M | -257.71M |
| Financing | 3.22M | 1.62M | 239.38M | 285.15M | 485.67M |
| Year End 30 November 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -80k | -84.37M | -159.81M | -81.37M | -172.58M |
| Investing | -254.4M | -108.25M | 27.2M | 68.3M | -257.71M |
| Financing | 339.02M | 153.88M | 117.19M | 3.22M | 485.67M |
| Market Cap | 1.33B |
| Price to Earnings Ratio | -6.89 |
| Price to Sales Ratio | 24.44 |
| Price to Cash Ratio | 12.12 |
| Price to Book Ratio | 2.53 |
| Dividend Yield | - |
| Shares Outstanding | 75.89M |
| Average Volume (1 week) | 640.4k |
| Average Volume (1 Month) | 642.4k |
| 52 Week Change | 95.88% |
| 52 Week High | 29.56 |
| 52 Week Low | 8.84 |
| Spread (Intraday) | 2.1 (10.99%) |
| Company Name | Nurix Therapeutics Inc |
| Address |
3500 s dupont hwy dover, delaware 19901 |
| Website | https://www.nurixtx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
